Lupulone Compounds
- 詳細技術說明
- None
- *Abstract
-
Treatment with Low IC50 for Drug Resistant Cancers and BacteriaA recently developed lupulone compound and pharmaceutically acceptable delivery method have been shown to act in cancer inhibition and bacterial growth inhibition, even those that are resistant to multiple drugs. The compound, hexahydrocolupulone, is highly potent and has a relatively low IC50. The compound likely stops inhibition by interfering with the G1-S phase transition. This compound could be used in constructing a more effective agent for the treatment of multidrug resistant cancer lines and multidrug-resistant bacteria strains.A drug that is effective against multidrug resistant cancers and bacterial strains would have wide applications. Cancers, much like bacteria, can build up drug resistances. This results in more resilient cancers and more intensive and toxic treatment plans. A need exists for a drug compound that can effectively treat drug resistant cancers with minimal side effects. Certain acids extracted from hops, called lupulones, have been shown to inhibit the growth of microorganisms. Further research into these acids may produce treatments for multidrug resistant cancers as well as multidrug resistant bacteria.
- *Principal Investigation
-
Name: Emily Ngo, Researcher, PhD
Department:
- 附加資料
- Patent Number: US5827895A
Application Number: US1996717120A
Inventor: Nutter, Louise | Ngo, Emily O. | Stephan, Thomas | Mannering, Gilbert J.
Priority Date: 27 Feb 1996
Priority Number: US5827895A
Application Date: 20 Sep 1996
Publication Date: 27 Oct 1998
IPC Current: A61K003100 | A61K003112 | A61K0031122 | A61P003100 | A61P003104 | A61P003500
US Class: 514690 | 424405
Assignee Applicant: Regents of the University of Minnesotanneapolis
Title: Hexahydrolupulones useful as anticancer agents
Usefulness: Hexahydrolupulones useful as anticancer agents
Summary: USE (I) are known compounds which inhibit the growth of food pathogens such as Listeria monocytogenes, and also certain lactobacilli.Administration is parenteral, oral or topical (claimed). Dosage is 0.5-100 (preferably 15-60) mg/kg/day.
Novelty: Use of hexa:hydro-lupulone derivatives as antibacterial agents for inhibiting the growth of antibiotic-resistant Staphylococcus aureus (MRSA), Mycobacterium tuberculosis, Enterococcus etc.
- 主要類別
- 生物醫學
- 細分類別
- DNA /基因工程
- 國家/地區
- 美國
